University of Texas MD Anderson Cancer Center-1155 Pressler — Houston, Texas

University of Texas MD Anderson Cancer Center-1155 Pressler is a clinical research site located in Houston, Texas, United States 77030-2348.

Crixeo Clinical Trials Trust Score: 94/100 (GOOD). This profile has not yet been claimed by the site owner.

University of Texas MD Anderson Cancer Center-1155 Pressler has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: IgA Nephropathy, Immunoglobulin A Nephropathy.

Sponsors: Novartis Pharmaceuticals.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Houston

Browse all research sites in Texas · View every site in Houston

Sponsor Feasibility Report

Trust Score: 94/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of Texas MD Anderson Cancer Center-1155 Pressler?

University of Texas MD Anderson Cancer Center-1155 Pressler has a Crixeo Trust Score of 94/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of Texas MD Anderson Cancer Center-1155 Pressler conducted?

University of Texas MD Anderson Cancer Center-1155 Pressler has 1 clinical trials on record, with 1 currently active. Their work covers IgA Nephropathy, Immunoglobulin A Nephropathy.

Is University of Texas MD Anderson Cancer Center-1155 Pressler accredited by Crixeo Clinical Trials?

University of Texas MD Anderson Cancer Center-1155 Pressler has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of Texas MD Anderson Cancer Center-1155 Pressler?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.